Frontage Laboratories, Inc. announced that it has established a joint venture with Zhejiang Jiuzhou Pharmaceutical Co. Ltd. to provide enhanced access to high quality and economical API & intermediate development and manufacturing (CDMO) services to new US clients focused on New Chemical Entities (NCE) and vertically-integrated generic APIs that are developed through the combined efforts of Frontage and Jiuzhou. The venture, named FJ Pharma, LLC, will utilize Jiuzhou’s vast development and manufacturing infrastructures and experienced chemistry teams in China and Frontage’s API development team and CMC drug development services in the US. This relationship will help to efficiently support NCE development, more effectively reach clients interested in these services, and potentially offer vertically integrated finished products via Frontage’s affiliate drug product CDMO company, Frontida BioPharm, Inc. Jiuzhou and Frontage will continue to offer exceptional service to their existing clients following the formation of FJ Pharma.